JL1115EH - JL1115EH: Real-world assessment of dosing patterns and treatment outcomes in patients with chronic lymphocytic leukemia who initiated first-line single-agent ibrutinib in an integrated claims-based database

Full author listing

Nilanjan Ghosh(1), Ruibin Wang,(2), Zhijie Ding (3), Xiaoxiao Lu (3), Jinghua He (2), Heena Mavani (2), Zaina P. Qureshi (3), Kerry A. Rogers (4)

1) Levine Cancer Institute, Atrium Health, Charlotte, NC, 2) Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 3) Janssen Scientific Affairs, LLC, Horsham, PA, USA, 4) Division of Hematology, The Ohio State University, Columbus